Filing Analysis
CervoMed Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal notification of the earnings release issued on August 10, 2026.
π Key Facts
- Company announced financial results for the quarter ending June 30, 2026.
- The announcement was made via press release (Exhibit 99.1) on August 10, 2026.
- Filing is pursuant to Item 2.02 of Form 8-K.
CervoMed Inc. announced that its drug candidate, neflamapimod, has been granted an Innovation Passport for the UK's Innovative Licensing and Access Pathway (ILAP) to support its development for dementia with Lewy bodies.
π Key Facts
- Drug candidate: neflamapimod
- Regulatory Milestone: Granted UK 'Innovation Passport' via the ILAP pathway
- Target Indication: Dementia with Lewy bodies
- Filing Date: August 4, 2026
CervoMed Inc. issued a press release regarding clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, presented at the Alzheimer's Association International Conference 2026.
π Key Facts
- Data presented relates to neflamapimod for the treatment of dementia with Lewy bodies (DLB).
- The data includes clinical, plasma biomarker, and imaging results.
- Results support a planned Phase 3 dose based on PK-PD analysis.
- Analyses reinforce observed treatment effects in 'pure' DLB patients.
CervoMed Inc. announced the completion of enrollment for its Phase 2a clinical study of neflamapimod, targeting nonfluent variant primary progressive aphasia (FTD). The company also noted that interim results will be presented at the upcoming CTAD conference.
π Key Facts
- Completed enrollment in Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (FTD).
- Interim clinical trial results are expected to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference.
- The filing incorporates press release information regarding recent Nature Neuroscience publications supporting p38Ξ± inhibition as a therapeutic approach.
CervoMed Inc. has closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share. The transaction was conducted as an 'at-the-market' offering under Nasdaq rules.
π© Red Flags
- Dilution of existing shareholders through the issuance of 2.5 million new shares.
π Key Facts
- Closed the sale of 2,500,000 shares of common stock.
- Offering price: $4.00 per share.
- Total gross proceeds from this specific tranche: $10,000,000.
- The offering was a registered direct offering conducted at-the-market under Nasdaq rules.
CervoMed Inc. entered into a securities purchase agreement to conduct a registered direct offering of 2,500,000 shares at $4.00 per share, aiming to raise $10.0 million in gross proceeds for working capital and general corporate purposes.
π© Red Flags
- Dilution: Issuance of 2.5 million new shares will dilute existing shareholders.
- Placement Agent Warrants: The issuance of warrants to the placement agent can create further dilution upon exercise.
π Key Facts
- Offering size: 2,500,000 shares of common stock.
- Price per share: $4.00.
- Aggregate gross proceeds: $10.0 million (before fees).
- Expected closing date: On or about June 22, 2026.
- Placement Agent: H.C. Wainwright & Co., LLC.
- Warrant compensation: 6.0% cash fee plus warrants to purchase common stock equal to 6.0% of the shares issued in the offering.
- Warrant terms: Exercise price of $5.00 per share; 5-year expiration.
CervoMed Inc. announced that it received a notice of allowance from the USPTO for a new patent regarding the use of neflamapimod for treating dementia with Lewy bodies in patients without substantial Alzheimer's disease-like tau pathology.
π Key Facts
- Notice of allowance received from the USPTO on June 16, 2026.
- Patent covers the drug candidate neflamapimod for a specific patient population (dementia with Lewy bodies without substantial tau pathology).
- Intellectual property protection is expected to extend into 2042, excluding potential patent term extensions.
CervoMed Inc. filed an 8-K to disclose that it has posted a presentation regarding its business, clinical studies, and financial position on its investor relations website. The company notes that this information is summary in nature and should be read in conjunction with its SEC filings.
π Key Facts
- The filing date is June 15, 2026.
- The company published a presentation under the 'Investors β Events and Presentations' section of www.cervomed.com.
- The presentation covers business operations, clinical studies, development plans, and financial position.
- The company explicitly states it makes no admission regarding the materiality of the information contained in the presentation.
CervoMed Inc. entered into a securities purchase agreement for a private placement of 3,360,377 units, expected to generate approximately $10.5 million in gross proceeds. The funds are earmarked for the development of neflamapimod and general working capital.
π© Red Flags
- Related-party transactions: The Chair (Joshua Boger), CEO (John Alam), and a Director (Sylvie GrΓ©goire) are participating in the placement for 1,369,426 units.
- Significant dilution potential: The inclusion of multiple warrant series (Series B and C) and pre-funded warrants increases the potential share count significantly.
π Key Facts
- Gross proceeds expected to be ~$10.5 million, with potential for an additional $21.7 million if warrants are fully exercised for cash.
- Units are priced at $3.14 (Common Stock) or $3.139 (Pre-funded Warrants).
- Proceeds, combined with existing cash, are estimated to fund operations into the second quarter of 2027.
- Placement agents are receiving a combined fee of approximately 6% of gross proceeds.
- The offering includes Series B warrants (5-year term, $3.32 exercise price) and Series C warrants (12-month term, $3.14 exercise price).
CervoMed Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 8, 2026. All submitted proposals, including the election of directors and the ratification of the accounting firm, were approved.
π Key Facts
- Annual Meeting held on June 8, 2026, with a quorum representing 67.2% of outstanding shares (6,218,593 of 9,258,719 shares).
- Eight directors were elected to serve until the next Annual Meeting.
- RSM US LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Executive compensation for the year ended December 31, 2024, was approved on an advisory basis.
- Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan was approved.
CervoMed Inc. (CRVO) filed an 8-K on May 18, 2026, disclosing quarterly financial results and a Regulation FD disclosure revealing a critically short cash runway. With only approximately $12.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, the Company has explicitly stated it can only fund operations into September 2026 β roughly four months from the filing date β raising acute going concern implications for this clinical-stage biotech.
π© Red Flags
- Cash runway explicitly limited to September 2026 (~4 months from filing), indicating imminent funding crisis.
- Only $12.9 million in cash remaining β critically low for a clinical-stage biotech with ongoing operating expenses.
- Phrase 'as previously announced' suggests this liquidity shortfall is not new, implying limited progress on resolving the issue.
- Multiple 8-K items filed simultaneously (Items 2.02 and 7.01), a red flag escalator per analysis guidelines.
- Apparent date inconsistency in the filing: financial results described as 'three months ended December 31, 2026' while the report date is May 18, 2026 β may indicate reporting errors or internal control weaknesses.
- No mention of any capital raise, partnership, or strategic transaction to address the funding gap.
- CFO also serves as General Counsel, suggesting lean or stressed organizational structure typical of distressed micro-caps.
π Key Facts
- Cash, cash equivalents, and marketable securities totaled approximately $12.9 million as of March 31, 2026.
- Company explicitly disclosed cash runway is expected to last only into September 2026, approximately 4 months from filing date.
- Filing covers financial results for the three months ended December 31, 2026 (note: possible date inconsistency in the filing itself).
- Filing includes two substantive items: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The Regulation FD cash runway disclosure was characterized as 'as previously announced,' suggesting the liquidity situation has been known and has not improved.
- 8-K signed by William Elder, Chief Financial Officer & General Counsel.
- Company is listed on NASDAQ Capital Market under ticker CRVO.
- Company is a Delaware-incorporated entity headquartered in Boston, MA.
CervoMed Inc. announced positive data from its Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies (DLB). The data, presented at the 2026 American Academy of Neurology Annual Meeting, showed the drug increased basal forebrain volume and functional connectivity.
π Key Facts
- The data was presented at the 2026 American Academy of Neurology (AAN) Annual Meeting on April 22, 2026.
- The Phase 2b RewinD-LB trial evaluated neflamapimod in patients with dementia with Lewy bodies.
- Results demonstrated that neflamapimod increased basal forebrain volume and functional connectivity.
- The company has updated its investor presentation on its website to include these clinical findings.
CervoMed Inc. announced that it will present key aspects of its neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting. The presentation is scheduled for April 7, 2026, in Atlanta, GA.
π Key Facts
- The company is presenting at the 2026 Lewy Body Dementia Association Annual Meeting on April 7, 2026.
- The presentation focuses on the neflamapimod clinical program.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the presentation was included as Exhibit 99.1.
CervoMed Inc. announced the availability of an updated investor presentation on its website covering business operations, clinical studies, and financial position. The company intends to use this presentation for upcoming conferences and meetings with analysts and investors.
π Key Facts
- Filing date: March 23, 2026.
- Item 7.01 (Regulation FD Disclosure) used to announce updated investor materials.
- Presentation includes information on clinical studies, development plans, and financial position.
- Materials are hosted on the company's website under the 'Investors β Events and Presentations' section.
CervoMed Inc. announced new analyses from its Phase 2b RewinD-LB clinical trial of neflamapimod in patients with dementia with Lewy bodies. The findings, which include stratified data by plasma pTau181 levels and PK/PD analyses, will be presented at the AD/PD 2026 Conference on March 21, 2026.
π Key Facts
- The company is presenting data at the AD/PD 2026 Conference in Copenhagen, Denmark.
- Analyses focus on the Phase 2b RewinD-LB clinical trial of neflamapimod for dementia with Lewy bodies (DLB).
- New data suggests a greater treatment effect in patients with a reduced likelihood of Alzheimer's (AD) co-pathology, identified via plasma pTau181 subsets.
- The filing includes new PK/PD (pharmacokinetic/pharmacodynamic) analyses of the Phase 2b data.
CervoMed Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and updated its investor presentation materials.
π Key Facts
- Financial results for the quarter and full year ended December 31, 2025, were released on March 17, 2026.
- The company updated its investor presentation on its website under the 'Investors β Events and Presentations' section.
- The information in the filing was furnished under Items 2.02 and 7.01, which are not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1, the press release detailing the financial results.
CervoMed announced the successful completion of a Phase 1 study evaluating the pharmacokinetics of a new crystal form of its lead drug candidate, neflamapimod. The company also provided updates regarding its upcoming Phase 3 trial for dementia with Lewy bodies (DLB).
π Key Facts
- Successfully completed a Phase 1 healthy volunteer study for a new, stable crystal form of neflamapimod
- The study evaluated the pharmacokinetics of the drug product
- Provided updates regarding the planned Phase 3 trial in dementia with Lewy bodies (DLB)
- Information was disclosed via a press release and an updated investor presentation on March 4, 2026
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been selected for the EXPERTS-ALS platform. This platform is funded by the UK National Institute for Health and Care Research and motor neuron disease charities to facilitate rapid testing of ALS treatments.
π Key Facts
- Lead drug candidate: neflamapimod
- Selected for inclusion in the EXPERTS-ALS platform
- EXPERTS-ALS is funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities
- The selection aims to facilitate rapid testing of potential ALS treatments
CervoMed Inc. filed an 8-K to provide notice that certain business, clinical, and financial information has been made available via a presentation on the company's website under Regulation FD.
π Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- Information regarding business, clinical studies, development plans, and financial position was released via an investor presentation.
- The information is intended for use in conferences, meetings, and presentations to investors/analysts.
CervoMed Inc. issued an 8-K to disclose positive clinical data from its Phase 2b RewinD-LB trial regarding neflamapimod treatment for dementia with Lewy bodies (DLB). The results were presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference.
π Key Facts
- Announced new plasma biomarker data from the Phase 2b RewinD-LB trial.
- Data demonstrates neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration in DLB patients.
- Results were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego.
- The company provided two press releases via Exhibit 99.1 and 99.2 regarding treatment benefits and full trial results.
CervoMed Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings press release issued on November 10, 2025.
π Key Facts
- Reported date: November 10, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
CervoMed Inc. announced that it has received written feedback from the FDA regarding its proposed Phase 3 clinical trial design for neflamapimod in treating dementia with Lewy bodies. The company reported alignment with the FDA on key aspects of the trial design.
π Key Facts
- Received written feedback from the U.S. Food and Drug Administration (FDA) regarding Phase 3 clinical trial design.
- The focus of the trial is neflamapimod for patients with dementia with Lewy bodies.
- The company reported alignment with the FDA on key aspects of the proposed study.
CervoMed Inc. announced the appointment of David Quigley to its Board of Directors, expanding the board from seven to eight members. Mr. Quigley brings extensive life sciences and private capital expertise from a 25-year career at McKinsey & Company.
π Key Facts
- David Quigley appointed as director effective October 27, 2025.
- Board size expanded from seven to eight members.
- Mr. Quigley granted stock options for 16,200 shares at an exercise price of $7.02 per share.
- Options vest in 36 equal monthly installments starting October 31, 2025.
- Quigley previously served as Senior Partner and Global Head of Private Capital at McKinsey & Company.
CervoMed Inc. filed an 8-K to provide notice that certain business, clinical, and financial information has been made available via a presentation on the company's website under Regulation FD disclosure.
π Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
- Information disclosed includes business updates, clinical studies, development plans, and financial position.
- The disclosure was made via a presentation on the company's website under 'Investors β Events and Presentations'.
- The information is furnished but not filed for purposes of Section 18 of the Exchange Act.
CervoMed Inc. issued a press release announcing new data from its RewinD-LB Phase 2b clinical trial for neflamapimod in patients with dementia with Lewy bodies.
π Key Facts
- Announcement date: October 8, 2025
- Subject: New data from the RewinD-LB Phase 2b clinical trial
- Drug candidate: neflamapimod
- Indication: Dementia with Lewy bodies (DLB)
CervoMed Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 11, 2025.
π Key Facts
- Reporting period: Quarter ended June 30, 2025
- Report date: August 11, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
The company is providing notice that certain business, clinical, and financial information has been made available via a presentation on their corporate website. This filing serves as a Regulation FD disclosure to ensure all investors have access to the same summary information.
π Key Facts
- Information regarding business, clinical studies, development plans, and financial position is hosted at www.cervomed.com under 'Investors β Events and Presentations'.
- The presentation contains summary information intended to be viewed in context with SEC filings.
- Management reserves the right to update or revise information via other SEC filings or press releases.
CervoMed Inc. issued a press release regarding 32-week data from the extension phase of its RewinD-LB Phase 2b clinical trial for neflamapimod in patients with dementia with Lewy bodies.
π Key Facts
- Announced 32-week data from the Extension Phase of the RewinD-LB Phase 2b clinical trial.
- The trial evaluates neflamapimod in patients with dementia with Lewy bodies.
- Data includes results on reduction in plasma levels of Glial Fibrillary Acidic Protein (GFAP) at Week 32.
- Company reported that old and new capsules have a similar overall safety and tolerability profile during the extension phase.
CervoMed Inc. held its 2025 Annual Meeting of Stockholders on June 23, 2025. All proposals, including director elections and auditor ratification, were approved by the shareholders.
π Key Facts
- Annual Meeting held on June 23, 2025.
- Quorum was present with approximately 64.5% of shares outstanding (5,610,237 shares) represented at the meeting.
- All seven nominees for the Board of Directors were elected to serve until the next Annual Meeting or successors.
- RSM US LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The 2025 Equity Incentive Plan was approved by shareholders.
The company is providing notice that certain business, clinical, and financial information has been made available via a presentation on its corporate website under Item 7.01.
π Key Facts
- Information regarding business, clinical studies, development plans, and financial position was released via the company's website (www.cervomed.com) under 'Investors β Events and Presentations'.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information provided in the presentation is intended for informational purposes and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
CervoMed Inc. entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to sell up to $50,000,000 of common stock. The company also released its financial results for the quarter ended March 31, 2025.
π© Red Flags
- Potential for significant shareholder dilution due to the $50M ATM offering.
- Multiple items in a single filing (ATM agreement + earnings release).
π Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on May 12, 2025.
- The agreement allows for an aggregate offering price of up to $50,000,000 in common stock.
- The offering is an 'at-the-market' (ATM) type under Rule 415(a)(4).
- Sales Agent (Leerink Partners LLC) will receive a 3.0% compensation fee on aggregate gross proceeds.
- Sales will be conducted via the company's existing S-3 shelf registration statement (effective Oct 10, 2024).
- Company released Q1 2025 financial results (ended March 31, 2025) simultaneously.
CervoMed Inc. announced significant leadership restructuring involving the promotion of two executives and the departure of its Chief Operating Officer. The company is replacing COO Robert J. Cobuzzi, Jr., Ph.D., with new executive appointments in Clinical Development and Regulatory Affairs.
π© Red Flags
- Departure of a C-suite officer (COO) often signals internal restructuring or strategic shifts.
- Significant cash outflow for severance: Total estimated lump-sum payments to departing COO exceed $599,000 plus COBRA costs.
π Key Facts
- Kelly Blackburn, M.H.A., appointed Executive Vice President, Clinical Development effective April 16, 2025 (Base salary: $448,360).
- Mark De Rosch, Ph.D., appointed Executive Vice President, Regulatory and Government Affairs and Program Management effective May 1, 2025 (Base salary: $465,000).
- COO Robert J. Cobuzzi, Jr., Ph.D., will depart the company effective July 1, 2025.
- Dr. Cobuzzi's separation package includes a lump-sum payment of $479,723 (12 months salary), $119,602 (pro-rated bonus), and 12 months of COBRA coverage.
- All stock options previously granted to Dr. Cobuzzi will remain exercisable through September 30, 2026.
CervoMed Inc. issued an 8-K to announce clinical results from the first sixteen weeks of the open-label extension phase of its RewinD-LB Phase 2b clinical trial for neflamapimod in patients with dementia with Lewy bodies.
π Key Facts
- Clinical results released for the first 16 weeks of the RewinD-LB Phase 2b open-label extension phase.
- The study focuses on the efficacy/safety of neflamapimod in patients with dementia with Lewy bodies.
- Information was disclosed via a press release issued on April 2, 2025.
CervoMed Inc. filed an 8-K to announce its financial results for the quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the earnings press release issued on March 17, 2025.
π Key Facts
- Reported date: March 17, 2025
- Reporting period: Quarter and full year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
CervoMed Inc. filed an 8-K to provide notice that certain business, clinical, and financial information has been made available on the company's website via investor presentations. This is a standard regulatory disclosure under Regulation FD.
π Key Facts
- The filing relates to Item 7.01 (Regulation FD Disclosure).
- Information regarding business, clinical studies, development plans, and financial position is hosted on the company's website under 'Investors β Events and Presentations'.
- The disclosure is intended for use in conferences, meetings, and presentations with investors and analysts.
CervoMed Inc. announced positive clinical results from the first sixteen weeks of the open-label extension phase of its RewinD-LB Phase 2b trial for neflamapimod in patients with dementia with Lewy bodies.
π Key Facts
- Announced positive results from the first 16 weeks of the RewinD-LB Phase 2b open-label extension phase.
- The study evaluates neflamapimod for treating patients with dementia with Lewy bodies.
- Data was released via press release on March 10, 2025.
CervoMed Inc. issued an 8-K to provide a clinical update on its neflamapimod development program for dementia with Lewy bodies, presented at the 8th International Lewy Body Dementia Conference (ILDBC). The filing serves as a regulatory vehicle to incorporate press release and presentation materials into the public record.
π Key Facts
- Company issued a press release on January 31, 2025, regarding its neflamapimod development program.
- The update was presented at the 8th International Lewy Body Dementia Conference (ILDBC).
- Information pertains to clinical studies and development plans for dementia with Lewy bodies.
- Presentation materials are made available on the company's investor relations website.
CervoMed Inc. issued a press release announcing topline data from its RewinD-LB Phase 2b clinical trial for patients with dementia with Lewy bodies and updated its corporate presentation.
π Key Facts
- Announced topline data from the RewinD-LB Phase 2b clinical trial on December 10, 2024.
- The trial focused on patients with dementia with Lewy bodies.
- Released an updated corporate presentation detailing business and development plans.
The company is providing notice that certain business, clinical, and financial information has been made available via a presentation on their website. This filing is used to satisfy Regulation FD requirements for non-public material information shared in investor presentations.
π Key Facts
- Information regarding business, clinical studies, development plans, and financial position was released under the 'Investors β Events and Presentations' section of the company website.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information provided in the presentation is considered 'furnished' rather than 'filed' for purposes of Section 18 of the Exchange Act.
CervoMed Inc. announced that the FDA has granted Orphan Drug Designation to its oral investigational drug, neflamapimod, for the treatment of frontotemporal dementia.
π Key Facts
- FDA granted Orphan Drug Designation for neflamapimod on November 27, 2024.
- The designation is specifically for the treatment of frontotemporal dementia.
- The drug in question is an oral investigational agent.
CervoMed Inc. filed an 8-K reporting quarterly financial results for the period ended September 30, 2024, announcing a prestigious industry award and key senior leadership appointments.
π Key Facts
- Released Q3 2024 financial results on November 12, 2024 (Item 2.02).
- Awarded the Prix Galien USA 2024 prize in the 'Best Startup' category by the Galien Foundation.
- Announced two new senior leadership appointments accompanied by inducement option awards on November 13, 2024.
CervoMed Inc. issued an 8-K to announce key takeaways from two oral presentations regarding its drug candidate, neflamapimod, presented at the Clinical Trials on Alzheimerβs Disease Conference.
π Key Facts
- Company announced results/takeaways for neflamapimod treatment for dementia with Lewy bodies.
- Presentations were delivered at the Clinical Trials on Alzheimerβs Disease Conference.
- The filing is a formal announcement of clinical data presentations via press release (Exhibit 99.1).
CervoMed Inc. announced it will present oral results from its RewinD-LB Phase 2b clinical trial of neflamapimod for dementia with Lewy bodies at the International Lewy Body Dementia Conference in January 2025.
π Key Facts
- Company to deliver an oral presentation on safety and efficacy results of neflamapimod.
- Trial name: RewinD-LB Phase 2b clinical trial.
- Indication: dementia with Lewy bodies.
- Event: eighth International Lewy Body Dementia Conference.
- Conference Date: January 29-31, 2025.
- Location: Amsterdam, the Netherlands.
CervoMed Inc. announced the completion of the last patient, last visit in its RewinD-LB Phase 2b clinical trial for neflamapimod in treating early-stage dementia with Lewy bodies (DLB). This marks a significant operational milestone in the company's clinical development pipeline.
π Key Facts
- Completed 'last patient, last visit' for the RewinD-LB Trial on October 15, 2024.
- The trial is a Phase 2b study evaluating neflamapimod.
- Target indication: patients with early-stage dementia with Lewy bodies (DLB).
CervoMed Inc. has announced the termination of its $20 million At-The-Market (ATM) Sales Agreement with BTIG, LLC, effective October 11, 2024. The company reported that no shares were sold under this agreement prior to the termination notice.
π© Red Flags
- Termination of an ATM program can sometimes indicate a shift in financing strategy, though here it is noted that no shares were ever sold under the agreement.
π Key Facts
- Termination of ATM Sales Agreement with BTIG, LLC is effective October 11, 2024.
- The original agreement dated July 22, 2022, allowed for the sale of up to $20,000,000 in common stock.
- No shares were sold under this specific ATM offering prior to termination.
- The company will not incur any penalties or expenses related to this termination.
CervoMed Inc. announced it will deliver two oral presentations regarding its drug candidate neflamapimod for the treatment of dementia with Lewy bodies (DLB) at the upcoming CTAD conference in October 2024.
π Key Facts
- Company to present data on neflamapimod for Dementia with Lewy Bodies (DLB).
- Presentations will occur at the Clinical Trials on Alzheimerβs Disease Conference (CTAD).
- Conference dates: October 29 β November 1, 2024.
- Location: Madrid, Spain.
CervoMed Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice that earnings information has been released via press release and made available on the company's website.
π Key Facts
- Report date: August 12, 2024
- Filing date: August 15, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- Information regarding business and clinical studies is available on the company's investor website.
CervoMed Inc. announced the presentation of plasma biomarker data from its AscenD-LB Phase 2a trial at a major Alzheimer's conference and management's upcoming participation in an industry growth conference.
π Key Facts
- Plasma biomarker data from the AscenD-LB Phase 2a trial (neflamapimod) was featured at the Alzheimer's Association International Conference (July 28 - August 1, 2024).
- Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.
- The filing includes two press releases as exhibits (99.1 and 99.2).
CervoMed Inc. announced a virtual key opinion leader (KOL) event scheduled for July 23, 2024. The presentation will focus on neflamapimod for the treatment of patients with dementia with Lewy bodies.
π Key Facts
- The company is hosting a virtual KOL event regarding its drug candidate neflamapimod.
- The event focuses on clinical applications for dementia with Lewy bodies.
- Presentation materials are made available via the 'Investors β Events and Presentations' section of the company website.
CervoMed Inc. announced its intention to host a virtual key opinion leader (KOL) event on July 23, 2024, regarding neflamapimod for the treatment of dementia with Lewy bodies.
π Key Facts
- The company will host a virtual KOL event on July 23, 2024.
- The event focuses on neflamapimod for treating patients with dementia with Lewy bodies.
- The announcement was made via press release issued on July 11, 2024.
CervoMed Inc. held its 2024 Annual Meeting of Stockholders, where all proposed itemsβincluding director elections and auditor ratificationβwere approved. Additionally, the company announced the completion of enrollment for its Phase 2b RewinD-LB clinical trial.
π Key Facts
- Annual Meeting held on June 14, 2024; quorum was present with ~78.35% of shares outstanding represented.
- Eight nominees were elected to the Board of Directors by plurality vote.
- RSM US LLP was ratified as the independent registered public accounting firm for the fiscal year ending Dec 31, 2024.
- Say-on-pay (executive compensation) was approved on an advisory basis.
- The company completed enrollment in its Phase 2b RewinD-LB clinical trial for neflamapimod to treat dementia with Lewy bodies.
CervoMed Inc. announced a leadership transition in its finance department, where current CFO William Tanner, Ph.D. will transition to a consulting role effective June 1, 2024. He will be succeeded by the company's General Counsel, William Elder, who will assume the CFO role and serve as Principal Financial and Accounting Officer.
π© Red Flags
- CFO transition: The departure of a CFO often signals internal shifts or strategic changes, though the transition to a consulting role suggests an attempt at continuity.
- Significant severance/consulting costs for departing executive.
π Key Facts
- William Tanner, Ph.D. (CFO) to transition to a consulting role effective June 1, 2024.
- William Elder (current General Counsel/Corporate Secretary) appointed as CFO, effective June 1, 2024.
- Dr. Tanner's separation includes a lump-sum payment of $162,000 (9 months base salary), a pro-rated bonus of $31,397, and an additional $31,603.
- Dr. Tanner will remain as a consultant through December 31, 2025, at a rate of $450 per hour.
- William Elder's new compensation includes a base salary of $429,000 and a target bonus opportunity of 35%.
CervoMed Inc. filed an 8-K to announce the release of its financial results for the quarter ended March 31, 2024.
π Key Facts
- Report date: May 15, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard earnings press release announcement under Item 2.02.
CervoMed Inc. filed an 8-K to provide notice of a corporate presentation containing information regarding business operations, clinical studies, and financial position. The filing also provides an update on the total number of shares issued and outstanding.
π Key Facts
- The company made business, clinical study, development plan, and financial position information available via its website under 'Investors β Events and Presentations'.
- As of April 22, 2024, there are 8,253,741 shares of common stock issued and outstanding.
- The presentation is furnished pursuant to Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
CervoMed Inc. filed an 8-K to announce the release of its financial results for the quarter and full year ended December 31, 2023.
π Key Facts
- Report date: April 1, 2024
- Filing date: April 5, 2024
- Covers financial results for the quarter and full year ended December 31, 2023
- Earnings press release issued via Exhibit 99.1
The company is providing notice that certain business, clinical, and financial information has been made available via corporate presentations on their website. This filing is a standard regulatory disclosure under Item 7.01 to ensure compliance with Regulation FD.
π Key Facts
- Information regarding business, clinical studies, development plans, and financial position was released via investor presentations.
- Presentations are located at www.cervomed.com under 'Investors β Events and Presentations'.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
CervoMed Inc. entered into a securities purchase agreement for a private placement of 2,532,285 units, expected to raise approximately $50 million in gross proceeds. The funds are intended to support R&D for neflamapimod and provide working capital through the end of 2025.
π© Red Flags
- Significant potential dilution via Series A Warrants and Pre-Funded Warrants.
π Key Facts
- Private placement of 2,532,285 units consisting of Common Stock/Pre-Funded Warrants and Series A Warrants.
- Expected gross proceeds: ~$50 million upfront; up to an additional $99.4 million if Series A warrants are fully exercised.
- Unit pricing: $19.745 for stock + warrant units; $19.744 for pre-funded warrant units.
- Series A Warrants have an exercise price of $39.24 (a 100% premium to the last sale price).
- Estimated cash runway: Sufficient to fund operations through the end of 2025.
- Placement Agents: Morgan Stanley and Canaccord Genuity (6% combined fee).
CervoMed Inc. has announced the date for its 2024 annual meeting of stockholders, scheduled for June 14, 2024. The company also provided instructions and deadlines for shareholders wishing to submit proposals or director nominations.
π Key Facts
- Annual Meeting Date: June 14, 2024
- Meeting Format: Virtual via remote communication
- Proposal Deadline: April 1, 2024 (close of business)
- Submission Method: Email to Corporate Secretary at info@cervomed.com
CervoMed Inc. issued an 8-K to announce the presentation of biomarker data from its AscenD-LB Phase 2a trial at the AD/PDβ’ 2024 conference. The filing serves as a vehicle for Regulation FD disclosure regarding clinical study results.
π Key Facts
- Company presented neflamapimod biomarker data from the AscenD-LB Phase 2a trial.
- The presentation occurred at the 18th International Conference on Alzheimerβs and Parkinsonβs Diseases (AD/PDβ’) 2024.
- Conference dates: March 5β9, 2024.
- Data pertains to patients with dementia with Lewy bodies.
CervoMed Inc. amended a pre-funded warrant held by The Joshua S. Boger 2021 Trust to remove a 9.99% beneficial ownership limitation, which subsequently triggered the full cashless exercise of the warrants.
π© Red Flags
- Related-party transaction: The warrant holder is a trust for Joshua S. Boger, who was appointed Chair of the Board effective February 7, 2024.
- Concentration risk: A single entity (the Trust) just significantly increased its ownership stake by removing beneficial ownership caps.
π Key Facts
- On February 26, 2024, the Company and The Joshua S. Boger 2021 Trust entered into an amendment to a Pre-Funded Warrant.
- The Amendment eliminated the restriction preventing the Holder from exercising warrants that would result in >9.99% beneficial ownership.
- Following the amendment, the Trust exercised the warrant in full via cashless exercise, receiving 495,959 shares of common stock.
- As of February 27, 2024, total outstanding common stock increased to 6,170,479 shares.
CervoMed Inc. announced the appointment of Joshua S. Boger, Ph.D., as a new Director and Chair of the Board, effective February 7, 2024. Dr. Boger is the founder of Vertex Pharmaceuticals and brings significant biotechnology leadership to the company.
π© Red Flags
- Related-party transactions: Dr. Boger and affiliated trusts purchased $5.5M of EIP Convertible Notes in 2020/2021.
- Dr. Boger holds a significant ownership stake (approx. 9.9%) which is near the 10% beneficial ownership threshold.
π Key Facts
- Joshua S. Boger, Ph.D., appointed as Director and Chair of the Board effective Feb 7, 2024.
- Dr. Boger is the founder and former CEO/Chairman of Vertex Pharmaceuticals (NASDAQ: VRTX).
- The Board size expanded from seven to eight members.
- Dr. Boger will receive a stock option for 10,000 shares vesting in 36 monthly installments starting Feb 29, 2024.
- Dr. Boger currently holds approximately 9.90% of the Company's common stock (561,309 shares) plus pre-funded warrants for an additional 495,995 shares.
CervoMed Inc. entered into new employment agreements with its top three executives: CEO John Alam, COO Robert J. Cobuzzi, Jr., and SVP of Clinical Development Kelly Blackburn, effective February 1, 2024.
π© Red Flags
- Significant severance/change in control payouts (up to 200% of salary + bonus) could create high cash outflows during a merger or acquisition scenario.
π Key Facts
- Dr. John Alam (CEO) received an initial annual base salary of $538,534.86 with a 50% target bonus opportunity.
- Dr. Robert J. Cobuzzi, Jr. (COO) received an initial annual base salary of $465,750.00 with a 50% target bonus opportunity.
- Kelly Blackburn (SVP, Clinical Development) received an initial annual base salary of $316,549.78 with a 35% target bonus opportunity.
- New agreements include significant severance provisions in the event of termination without cause or resignation for good reason, particularly around Change of Control events.
- Executives are subject to non-competition and non-solicitation restrictive covenants for up to 24 months post-employment.
CervoMed Inc. announced that members of its senior management team will be presenting at the Emerging Growth Conference 66 on January 11, 2024.
π Key Facts
- Management presentation scheduled for Thursday, January 11, 2024, at 11:25 a.m. ET.
- Event identified as Emerging Growth Conference 66.
- Filing includes an exhibit (99.1) containing the full press release.
CervoMed Inc. filed an 8-K to provide notice that corporate presentation materials regarding business, clinical studies, and financial position have been made available on the company's website.
π Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- Information includes updates on business operations, clinical studies, development plans, and financial position.
- Presentation materials are located under 'Investors β Events and Presentations' on the company website.